Gene Therapy Pioneer Wins $3M Breakthrough Prize

-approved gene therapy for blindness. Officials behind the prize highlighted the treatment’s impact on patients with Leber congenital amaurosis (LCA), a genetic disorder that typically progresses to total blindness by early adulthood.

The work recognized by the award spans a 25-year effort led by molecular biologist Bennett and ophthalmologist Maguire. Their project targeted faults in the RPE65 gene, which is responsible for LCA in the patients addressed by the therapy. Luxturna is designed to deliver a functional version of the RPE65 gene into retinal cells, with the aim of restoring visual function by enabling those cells to work more normally.

Clinical trials cited in the prize recognition showed what the researchers described as profound improvements in vision. According to accounts from the trials, some patients said they could see faces and fine details for the first time. The award places the Luxturna program among a set of advances that the Breakthrough Prizes said have helped move gene therapy from experimental promise toward approved medical use.

The ceremony also recognized other gene-therapy-related breakthroughs, underscoring the breadth of approaches now being used to treat genetic disease. Swee Lay Thein and Stuart Orkin were honored for work that contributed to a gene therapy for sickle cell anemia and beta thalassemia, which led to the development of Casgevy. The approach addresses faults in adult hemoglobin by disabling the BCL11A gene, a step intended to prompt cells to produce healthy fetal hemoglobin instead.

Beyond the scientific milestone, the awards draw attention to the growing strategic importance of advanced therapies for health systems, investors, and regulators. S. approval for a gene therapy for blindness and the development of a therapy such as Casgevy for blood disorders highlight how treatments can be tailored to specific genetic mechanisms, potentially reshaping how rare and inherited conditions are managed.

At the same time, the source material does not provide details on pricing, access, or how widely these therapies are available across countries, leaving uncertainty about near-term reach outside the settings where they have been developed and evaluated.